Displaying items by tag: oneal comprehensive cancer center

The drug Vismodegib, tested in a breast cancer model, is an inhibitor of hedgehog signaling, a form of cell communication manipulated by the tumor microenvironment.
Adaptive radiation therapy allows for more precise treatment by fine-tuning the treatment regimen based on up-to-date imaging.
The 14th annual Fiesta Ball, now happening for an entire week July 17-24, will have an online auction and participation from five local Mexican and Tex-Mex restaurants.
A small molecule inhibitor has been identified that reduces the growth of uveal melanoma, a rare and deadly cancer of the eye.

The largest coalition of biological and biomedical research associations in the United States, known as FASEB, advocates for the basic biomedical research community.

Elizabeth Brown, Ph.D., has received a $3.1 million grant from the National Cancer Institute to study epigenetic contribution to the excess risk of a precursor of multiple myeloma in African Americans.
The genetic counseling field has become an important component of medicine in the past decade. Alabama law now mandates all genetic counselors practicing in the state be licensed by fall of 2021.

The alliance will focus on boosting participation in clinical research within historically underrepresented patient groups. 

Gregory Friedman, M.D., has received a special grant to test various therapy combinations with a form of the herpes virus to improve anti-tumor immune response in children battling brain cancer.

The 14th annual Fiesta Ball, now happening for an entire week July 17-24, will have an online auction and participation from five local Mexican and Tex-Mex restaurants.
O’Neal Comprehensive Cancer Center at UAB is among three groups selected nationwide for the Co-Creating Solutions to Address Racism and Disparities in Oncology initiative coordinated by the Center for Health Care Strategies.
G207, an immunotherapy derived from a modified herpes virus is well tolerated in children with gliomas, and shows signs of clinical effectiveness
This digital solution will help doctors offer patients timely genetic testing for hereditary cancer, greater clinical support and counseling, coupled with shorter wait times and more counselors to expand into other clinical areas when needed.
The study points to an adhesive cell surface protein that might be a key element in tackling the resistance to radiation therapy commonly seen in glioblastoma tumors.
Proton International at UAB reached significant milestones in its first year. More than 5,000 treatments have been performed, with most patients getting 30-35 treatments. Some 142 patients have completed therapy.
Page 9 of 34